[Risk of euglycemic diabetic ketoacidosis due to low-carbohydrate diet while taking empagliflozin: a case report]
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Empagliflozin reduces blood glucose levels independently of insulin secretion by reducing glucose reabsorption in the proximal renal tubules through inhibition of sodium-glucose cotransporter 2 (SGLT2). Because SGLT2 inhibitors have a different mechanism of action to conventional antidiabetic drugs, recommendations have been issued about the management of specific side effect such as ketoacidosis, urinary tract infection, and genital infection. There have been some reports of SGLT2 inhibitor-associated euglycemic diabetic ketoacidosis (euDKA), but there have been few reports about euDKA in patients with type 2 diabetes using SGLT2 inhibitors while on a low-carbohydrate diet. Here we report a patient who developed euDKA after starting a very low-carbohydrate diet while taking empagliflozin. A 51-year-old man was hospitalized with nausea and vomiting, and investigations revealed metabolic acidosis. euDKA was diagnosed from the information about medications in his drug notebook and a history of eating a low-carbohydrate diet (1900 kcal, consisting of 5.7% carbohydrate, 21.1% protein, 47.3% fat and 25.9% alcohol) for 4 d. The patient improved after infusion of acetated Ringer's solution with 5% glucose and administration of regular insulin. It is necessary for physicians and pharmacists to thoroughly inform patients about the side effects of SGLT2 inhibitors such as ketoacidosis, urinary tract infection, and genital infection. Patients should also be advised about the higher risk of euDKA associated with a low-carbohydrate diet while taking SGLT2 inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Carbohydrate restricted ketogenic diets may increase the risk of SGLT2i-induced ketoacidosis [110].”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [110]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Hyperglycemic crises in adult patients with diabetes
Kitabchi, A. E., Umpierrez, G. E., Miles, J. M., & Fisher, J. N. (2009) · Diabetes Care · doi:10.2337/dc09-9032 · Cited by 2,062
Low-carbohydrate nutrition and metabolism
Westman, E. C., Feinman, R. D., Mavropoulos, J. C., Vernon, M. C., Volek, J. S., Wortman, J. A., Yancy, W. S., & Phinney, S. D. (2007) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/86.2.276 · Cited by 379
Handelsman, Y., Henry, R. R., Bloomgarden, Z. T., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Ferrannini, E., Fonseca, V. A., Garber, A. J., Grunberger, G., et al. (2016) · Endocrine Practice · doi:10.4158/ep161292.ps · Cited by 358
Goldenberg, R. M., Berard, L. D., Cheng, A. Y. Y., Gilbert, J. D., Verma, S., Woo, V. C., & Yale, J.-F. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.11.002 · Cited by 354
Japanese Clinical Practice Guideline for Diabetes 2016
Haneda, M., Noda, M., Origasa, H., Noto, H., Yabe, D., Fujita, Y., Goto, A., Kondo, T., & Araki, E. (2018) · Diabetology International · doi:10.1007/s13340-018-0345-3 · Cited by 319
Diabetic Ketoacidosis in Type 1 and Type 2 Diabetes Mellitus: Clinical and Biochemical Differences
Newton, C. A., & Raskin, P. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.17.1925 · Cited by 237
Euglycemic diabetic ketoacidosis
Barski, L., Eshkoli, T., Brandstaetter, E., & Jotkowitz, A. (2019) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2019.03.014 · Cited by 176
Fujita, Y., & Inagaki, N. (2014) · Journal of Diabetes Investigation · doi:10.1111/jdi.12214 · Cited by 148
Wang, Z. H., Kihl‐Selstam, E., & Eriksson, J. W. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02461.x · Cited by 120
Cited by
Scientific evidence underlying contraindications to the ketogenic diet: An update
Watanabe, M., Tuccinardi, D., Ernesti, I., Basciani, S., Mariani, S., Genco, A., Manfrini, S., Lubrano, C., & Gnessi, L. (2020) · Obesity Reviews · doi:10.1111/obr.13053 · Cited by 116
Dutta, S., Kumar, T., Singh, S., Ambwani, S. R., Charan, J., & Varthya, S. B. (2022) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_644_21 · Cited by 76
“, 2019[56] 51 y, M Empagliflozin T2DM Nausea and vomiting”
BackgroundBays, H. E., Fitch, A., Christensen, S., Burridge, K., & Tondt, J. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100018 · Cited by 68
“…acids are the main fuel for the heart, which has little glycogen) The prescribing information of SGLT-2 inhibitors describe reports of diabetes ketoacidosis in patients with type 2 diabetes mellitus Carbohydrate restricted ketogenic diets may increase the risk of SGLT2i-induced ketoacidosis [110].”
BackgroundÖzer, Ö., & Yorulmaz, G. (2020) · Journal of College of Physicians And Surgeons Pakistan · doi:10.29271/jcpsp.2020.supp2.110 · Cited by 13
Fieger, E., Fadel, K., Modarres, A. H., Wickham, E. P., & Wolver, S. E. (2020) · AACE Clinical Case Reports · doi:10.4158/accr-2020-0314 · Cited by 8
“Additionally, euDKA has been noted in multiple case reports when the VLCKD is coadministered with SGLT2 inhibitors, 3 of which are referenced here (16-18).”
Background
Metadata
- Authors
- Yamamoto, M., Ide, N., Kitajima, S., Obayashi, M., Asada, K., Matsushima, S., & Ito, M.
- Affiliations
- Chutoen General Medical Center (JP)
- Venue
- YAKUGAKU ZASSHI
- Publisher
- Pharmaceutical Society of Japan
- Published
- 2019-11-01
- Volume
- 139
- Issue
- 11
- Pages
- 1479-1483
- ISSN
- 0031-6903 (ISSN-L)
- 1347-5231
- OpenAlex
- W2986313496
- Cited by
- 7
- References
- 15
- Citations by year
- 2025: 1 · 2022: 2 · 2020: 4
- FWCI
- 1.22
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Locations
- YAKUGAKU ZASSHI (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Physiology (medical) › Diet and metabolism studies
- Keywords
- euglycemic diabetic ketoacidosis, empagliflozin, SGLT2 inhibitors, low-carbohydrate diet, type 2 diabetes, drug-induced ketoacidosis, metabolic acidosis, insulin therapy, patient education
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Glucose, Glucosides, Humans, Insulin, Isotonic Solutions, Male, Middle Aged, Risk, Diabetic Ketoacidosis, Treatment Outcome, Diet, Carbohydrate-Restricted
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: [Risk of euglycemic diabetic ketoacidosis due to low-carbohydrate diet while taking empagliflozin: a case report]. https://app.cochat.ai/papers/10.1248/yakushi.19-00120
- The paper
- Yamamoto, M., Ide, N., Kitajima, S., Obayashi, M., Asada, K., Matsushima, S., & Ito, M. (2019). [Risk of euglycemic diabetic ketoacidosis due to low-carbohydrate diet while taking empagliflozin: a case report]. YAKUGAKU ZASSHI. https://doi.org/10.1248/yakushi.19-00120
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.